In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Boston Scientific, with a price target of $120.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Travis Steed has given his Buy rating due to a combination of factors highlighting Boston Scientific’s strong growth potential in the electrophysiology (EP) market. Despite competition from Medtronic’s Affera, Boston Scientific is expected to continue experiencing profitable dollar growth, with the market conversion to pulse field ablation (PFA) benefiting both companies. The Street’s growth estimate of 10.7% for Boston Scientific in 2026 appears conservative, as the EP segment alone could contribute an additional 5 percentage points, with further contributions from products like Watchman and Champion.
Steed also sees significant upside potential for Boston Scientific compared to current Street estimates, projecting a 30% year-over-year growth in 2026 and 2027. This growth could lead to Boston Scientific achieving a leading position in the EP market by 2027, with an estimated market share increase to 32.5%. The analyst’s confidence is further supported by Boston Scientific’s ability to outperform Street expectations, suggesting a robust growth trajectory that justifies the Buy rating.